Memphasys Limited (MEM.AX)
AUD 0.01
(0.0%)
AUD 0.01
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -2.7 Million AUD | -44.17% |
| 2023 | -3.63 Million AUD | -34.24% |
| 2022 | -2.7 Million AUD | -59.84% |
| 2021 | -1.69 Million AUD | -34.22% |
| 2020 | -1.26 Million AUD | -16.41% |
| 2019 | -1.08 Million AUD | 7.2% |
| 2018 | -1.16 Million AUD | 44.63% |
| 2017 | -2.1 Million AUD | -18.9% |
| 2016 | -1.77 Million AUD | -8.36% |
| 2015 | -1.63 Million AUD | -2.54% |
| 2014 | -1.59 Million AUD | 50.21% |
| 2013 | -3.2 Million AUD | 26.63% |
| 2012 | -4.37 Million AUD | 12.32% |
| 2011 | -4.98 Million AUD | -564.54% |
| 2010 | -750.03 Thousand AUD | 78.53% |
| 2009 | -3.49 Million AUD | 45.36% |
| 2008 | -6.39 Million AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -2.49 Million AUD | 0.0% |
| 2024 FY | -5.23 Million AUD | -44.17% |
| 2024 Q4 | -2.74 Million AUD | 0.0% |
| 2023 Q2 | -1.25 Million AUD | 0.0% |
| 2023 Q4 | -2.38 Million AUD | 0.0% |
| 2023 FY | -3.63 Million AUD | -34.24% |
| 2022 Q2 | -802.7 Thousand AUD | 0.0% |
| 2022 Q4 | -1.28 Million AUD | 0.0% |
| 2022 FY | -2.7 Million AUD | -59.84% |
| 2021 Q2 | -732.42 Thousand AUD | 0.0% |
| 2021 FY | -1.69 Million AUD | -34.22% |
| 2021 Q4 | -969.09 Thousand AUD | 0.0% |
| 2020 Q4 | -516.41 Thousand AUD | 0.0% |
| 2020 Q2 | -745.32 Thousand AUD | 0.0% |
| 2020 FY | -1.26 Million AUD | -16.41% |
| 2019 Q2 | -585.19 Thousand AUD | 0.0% |
| 2019 Q4 | -498.66 Thousand AUD | 0.0% |
| 2019 FY | -1.08 Million AUD | 7.2% |
| 2018 FY | -1.16 Million AUD | 44.63% |
| 2018 Q2 | -717.23 Thousand AUD | 0.0% |
| 2018 Q4 | -450.65 Thousand AUD | 0.0% |
| 2017 Q2 | -857.15 Thousand AUD | 0.0% |
| 2017 FY | -2.1 Million AUD | -18.9% |
| 2016 FY | -1.77 Million AUD | -8.36% |
| 2016 Q2 | -1.09 Million AUD | 0.0% |
| 2015 Q2 | -1 Million AUD | 0.0% |
| 2015 FY | -1.63 Million AUD | -2.54% |
| 2014 Q1 | -724.55 Thousand AUD | 0.0% |
| 2014 FY | -1.59 Million AUD | 50.21% |
| 2014 Q4 | 19.64 Thousand AUD | 105.25% |
| 2014 Q3 | -374.49 Thousand AUD | 65.54% |
| 2014 Q2 | -1.08 Million AUD | -49.99% |
| 2013 Q3 | -724.55 Thousand AUD | 9.35% |
| 2013 FY | -3.2 Million AUD | 26.63% |
| 2013 Q4 | -724.55 Thousand AUD | 0.0% |
| 2013 Q2 | -799.3 Thousand AUD | 19.53% |
| 2013 Q1 | -993.24 Thousand AUD | 0.0% |
| 2012 Q2 | -993.24 Thousand AUD | 3.23% |
| 2012 Q3 | -993.24 Thousand AUD | 0.0% |
| 2012 Q4 | -993.24 Thousand AUD | 0.0% |
| 2012 FY | -4.37 Million AUD | 12.32% |
| 2012 Q1 | -1.02 Million AUD | 0.0% |
| 2011 FY | -4.98 Million AUD | -564.54% |
| 2011 Q1 | -95.21 Thousand AUD | 0.0% |
| 2011 Q3 | -1.02 Million AUD | 0.0% |
| 2011 Q4 | -1.02 Million AUD | 0.0% |
| 2011 Q2 | -1.02 Million AUD | -978.06% |
| 2010 Q2 | -95.21 Thousand AUD | 87.65% |
| 2010 Q3 | -95.21 Thousand AUD | 0.0% |
| 2010 Q1 | -771.16 Thousand AUD | 0.0% |
| 2010 Q4 | -95.21 Thousand AUD | 0.0% |
| 2010 FY | -750.03 Thousand AUD | 78.53% |
| 2009 Q1 | -1.45 Million AUD | 0.0% |
| 2009 Q4 | -771.16 Thousand AUD | 0.0% |
| 2009 FY | -3.49 Million AUD | 45.36% |
| 2009 Q3 | -771.16 Thousand AUD | 0.0% |
| 2009 Q2 | -771.16 Thousand AUD | 46.88% |
| 2008 Q3 | -1.45 Million AUD | 0.0% |
| 2008 FY | -6.39 Million AUD | 0.0% |
| 2008 Q4 | -1.45 Million AUD | 0.0% |
| 2008 Q2 | -1.45 Million AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 9.71 Million AUD | 127.829% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -85.316% |
| Zelira Therapeutics Limited | -5.93 Million AUD | 54.465% |
| Biome Australia Limited | -1.91 Million AUD | -41.331% |
| Patrys Limited | -3.53 Million AUD | 23.597% |
| Orthocell Limited | -11.68 Million AUD | 76.852% |
| Imugene Limited | -140.93 Million AUD | 98.081% |
| Noxopharm Limited | -7.53 Million AUD | 64.114% |
| PYC Therapeutics Limited | -38.85 Million AUD | 93.041% |
| Chimeric Therapeutics Limited | -12.3 Million AUD | 78.034% |
| Prescient Therapeutics Limited | -7.18 Million AUD | 62.373% |
| Proteomics International Laboratories Limited | -7.23 Million AUD | 62.608% |
| Cynata Therapeutics Limited | -8.8 Million AUD | 69.3% |
| CSL Limited | 5.64 Billion AUD | 100.048% |
| Arovella Therapeutics Limited | -7.19 Million AUD | 62.408% |
| Bio-Gene Technology Limited | -3.06 Million AUD | 11.705% |
| Clinuvel Pharmaceuticals Limited | 49.14 Million AUD | 105.502% |
| Starpharma Holdings Limited | -15.15 Million AUD | 82.162% |
| Nanollose Limited | -1.24 Million AUD | -116.35% |
| Invex Therapeutics Ltd | -2.13 Million AUD | -26.733% |
| NeuroScientific Biopharmaceuticals Limited | -2.05 Million AUD | -31.482% |
| Amplia Therapeutics Limited | -4.42 Million AUD | 38.892% |
| Botanix Pharmaceuticals Limited | -14.69 Million AUD | 81.605% |
| Island Pharmaceuticals Limited | -2.87 Million AUD | 5.908% |
| Race Oncology Limited | -13.38 Million AUD | 79.792% |
| Nyrada Inc. | -4.56 Million AUD | 40.706% |
| Telix Pharmaceuticals Limited | - AUD | Infinity% |
| Dimerix Limited | -25.05 Million AUD | 89.21% |
| PharmAust Limited | -6.65 Million AUD | 59.391% |
| Immutep Limited | -44.93 Million AUD | 93.983% |
| Clarity Pharmaceuticals Ltd | -44.8 Million AUD | 93.964% |
| Alterity Therapeutics Limited | -19.6 Million AUD | 86.205% |
| BTC Health Limited | 1.05 Million AUD | 356.234% |
| Acrux Limited | -9.83 Million AUD | 72.504% |
| Neuren Pharmaceuticals Limited | 225.96 Million AUD | 101.197% |
| Biotron Limited | -5.15 Million AUD | 47.507% |
| Tissue Repair Ltd | -4.87 Million AUD | 44.544% |
| AdAlta Limited | -5.26 Million AUD | 48.609% |
| Radiopharm Theranostics Limited | -47.2 Million AUD | 94.272% |
| Hexima Limited | -1 Million AUD | -168.055% |
| AnteoTech Limited | -11.72 Million AUD | 76.941% |
| Paradigm Biopharmaceuticals Limited | -65.11 Million AUD | 95.847% |
| Recce Pharmaceuticals Ltd | -22.05 Million AUD | 87.738% |
| Avecho Biotechnology Limited | -4.58 Million AUD | 41.079% |
| Actinogen Medical Limited | -12.83 Million AUD | 78.939% |
| Immuron Limited | -5.8 Million AUD | 53.388% |
| Argenica Therapeutics Limited | -5.67 Million AUD | 52.321% |